Matrix metalloproteinase-2 polymorphism is associated with prognosis in prostate cancer

详细信息    查看全文

• 作者：Sabrina Thalita dos Reis ; Fabiola Elizabeth Villanova ; Priscila Maria Andrade ; José ; Pontes Jr. ; Juliana Moreira de Sousa-Canavez ; Adriana Sa&#xf1 ; udo ; Alberto Azoubel Antunes ; Marcos Francisco Da
• 关键词：Disease susceptibility ; Metalloproteinases ; Polymorphism ; Prognosis ; Prostate cancer
• 刊名：Urologic Oncology: Seminars and Original Investigations
• 出版年：2010
• 出版时间：November-December 2010
• 年：2010
• 卷：28
• 期：6
• 页码：624-627
• 全文大小：142 K

文摘

Objective

Prostate cancer (PCa) is the most frequent tumor in males in Brazil. Single nucleotide polymorphisms (SNP) have been demonstrated in the promoter region of matrix metalloproteinases (MMPs) genes and have been associated with development and progression of some cancers. In this study, our aim was to investigate a possible relation between polymorphism of the promoter region of the MMP2 gene and classical prognostic parameters in prostate cancer.

Materials and methods

Genomic DNA was extracted using conventional protocols. The DNA sequence containing the polymorphic site was amplified by real-time polymerase chain reaction, using fluorescent probes (TaqMan).

Results

In patients with tumors of a higher stage (pT3), a polymorphic allele in the MMP2 gene was more frequent (P = 0.026) than in patients with lower tumor stage. A polymorphic allele in the MMP2 gene was more frequent in Gleason ≥ 7 than in Gleason ≤ 6 (P = 0.042).

Conclusions

We conclude that MMP2 polymorphism can be used together with pathological stage and Gleason score to identify patients with worse prognosis. Our results illustrate the potential use of MMP2 SNP as a molecular marker for prostate cancer.